284 related articles for article (PubMed ID: 34031411)
41. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
[TBL] [Abstract][Full Text] [Related]
42. SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis.
Jiang K; Liu P; Xu H; Liang D; Fang K; Du S; Cheng W; Ye L; Liu T; Zhang X; Gong P; Shao S; Wang Y; Meng S
Oncogene; 2020 Jul; 39(27):5015-5030. PubMed ID: 32523092
[TBL] [Abstract][Full Text] [Related]
43. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
[No Abstract] [Full Text] [Related]
44. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon.
Zhu Y; Zhang D; Shukla P; Jung YH; Malgulwar PB; Chagani S; Colic M; Benjamin S; Copland JA; Tan L; Lorenzi PL; Javle M; Huse JT; Roszik J; Hart T; Kwong LN
JCI Insight; 2024 Jan; 9(2):. PubMed ID: 38060314
[TBL] [Abstract][Full Text] [Related]
45. In vivo CRISPR screens identify RhoV as a pro-metastasis factor of triple-negative breast cancer.
Jin ML; Gong Y; Ji P; Hu X; Shao ZM
Cancer Sci; 2023 Jun; 114(6):2375-2385. PubMed ID: 36898847
[TBL] [Abstract][Full Text] [Related]
46. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
47. Expression of mTOR Signaling Pathway Molecules in Triple-Negative Breast Cancer.
Ito K; Ogata H; Honma N; Shibuya K; Mikami T
Pathobiology; 2019; 86(5-6):315-321. PubMed ID: 31707383
[TBL] [Abstract][Full Text] [Related]
48. Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program.
Luan H; Mohapatra B; Bielecki TA; Mushtaq I; Mirza S; Jennings TA; Clubb RJ; An W; Ahmed D; El-Ansari R; Storck MD; Mishra NK; Guda C; Sheinin YM; Meza JL; Raja S; Rakha EA; Band V; Band H
Cancer Res; 2018 May; 78(10):2524-2535. PubMed ID: 29510992
[TBL] [Abstract][Full Text] [Related]
49. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
50. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
[No Abstract] [Full Text] [Related]
51. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
Robles AJ; Cai S; Cichewicz RH; Mooberry SL
Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
[TBL] [Abstract][Full Text] [Related]
52. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
53. Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer.
Xu ST; Xu JH; Zheng ZR; Zhao QQ; Zeng XS; Cheng SX; Liang YH; Hu QF
Biomed Pharmacother; 2017 Dec; 96():14-21. PubMed ID: 28961506
[TBL] [Abstract][Full Text] [Related]
54. GPER/Hippo-YAP signal is involved in Bisphenol S induced migration of triple negative breast cancer (TNBC) cells.
Deng Q; Jiang G; Wu Y; Li J; Liang W; Chen L; Su Q; Li W; Du J; Wong CKC; Chen Z; Wang H
J Hazard Mater; 2018 Aug; 355():1-9. PubMed ID: 29758456
[TBL] [Abstract][Full Text] [Related]
55. Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9-coupled Affinity Purification/Mass Spectrometry Analysis Revealed a Novel Role of Neurofibromin in mTOR Signaling.
Li X; Gao M; Choi JM; Kim BJ; Zhou MT; Chen Z; Jain AN; Jung SY; Yuan J; Wang W; Wang Y; Chen J
Mol Cell Proteomics; 2017 Apr; 16(4):594-607. PubMed ID: 28174230
[TBL] [Abstract][Full Text] [Related]
56. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
57. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
[TBL] [Abstract][Full Text] [Related]
58. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
59. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
60. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
